BioMarin Pharmaceutical (1BMRN) Stock Overview
A biotechnology company, engages in the development and commercialization of therapies for life-threatening rare diseases and medical conditions in the United States, Europe, Latin America, the Middle East, the Asia Pacific, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 3/6 |
| Past Performance | 3/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
1BMRN Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Looking to be second time lucky with a game-changing new product
Key Takeaways Unicycive has successfully completed clinical development of its lead asset, Oxylanthanum Carbonate (OLC). OLC has been designed to improve on current phosphate binders by offering better efficacy, fewer pills, and improved tolerability over alternative treatments for hyperphosphatemia chronic kidney disease patients on dialysis.Read more
BioMarin Pharmaceutical Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$49.05 |
| 52 Week High | US$66.34 |
| 52 Week Low | US$43.05 |
| Beta | 0.26 |
| 1 Month Change | -3.25% |
| 3 Month Change | 7.64% |
| 1 Year Change | -18.98% |
| 3 Year Change | -52.65% |
| 5 Year Change | -31.21% |
| Change since IPO | -31.92% |
Recent News & Updates
Recent updates
Shareholder Returns
| 1BMRN | IT Biotechs | IT Market | |
|---|---|---|---|
| 7D | 3.6% | -0.0004% | 2.0% |
| 1Y | -19.0% | 18.7% | 25.0% |
Return vs Industry: 1BMRN underperformed the Italian Biotechs industry which returned 18.7% over the past year.
Return vs Market: 1BMRN underperformed the Italian Market which returned 25% over the past year.
Price Volatility
| 1BMRN volatility | |
|---|---|
| 1BMRN Average Weekly Movement | 7.2% |
| Biotechs Industry Average Movement | 7.9% |
| Market Average Movement | 4.1% |
| 10% most volatile stocks in IT Market | 7.2% |
| 10% least volatile stocks in IT Market | 2.5% |
Stable Share Price: 1BMRN's share price has been volatile over the past 3 months compared to the Italian market.
Volatility Over Time: 1BMRN's weekly volatility (7%) has been stable over the past year, but is still higher than 75% of Italian stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1996 | 3,040 | Alexander Hardy | www.biomarin.com |
BioMarin Pharmaceutical Inc., a biotechnology company, engages in the development and commercialization of therapies for life-threatening rare diseases and medical conditions in the United States, Europe, Latin America, the Middle East, the Asia Pacific, and internationally. The company’s products include VIMIZIM, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; VOXZOGO, a once daily injection analog of c-type natriuretic peptide (CNP) for the treatment of achondroplasia; NAGLAZYME, a recombinant form of N- acetylgalactosamine 4-sulfatase for patients with MPS VI; and PALYNZIQ, a PEGylated recombinant phenylalanine (Phe) ammonia lyase enzyme delivered through subcutaneous injection to reduce blood Phe concentrations. It also develops BRINEURA, a recombinant human tripeptidyl peptidase 1 for the treatment of patients with ceroid lipofuscinosis type 2, a form of Batten disease; ALDURAZYME, a purified protein designed to be identical to a naturally occurring form of the human enzyme alpha-L-iduronidase; KUVAN, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria, an inherited metabolic disease; and ROCTAVIAN, an adeno associated virus vector for the treatment of severe hemophilia A. The company’s products under development include BMN 333, a longer-acting CNP for the treatment of multiple growth disorders, such as achondroplasia and hypochondroplasia; BMN 349, an oral therapeutic for the treatment of liver disease associated with alpha-1 antitrypsin deficiency; and BMN 351, an oligonucleotide for the treatment of duchenne muscular dystrophy.
BioMarin Pharmaceutical Inc. Fundamentals Summary
| 1BMRN fundamental statistics | |
|---|---|
| Market cap | €9.44b |
| Earnings (TTM) | €441.42m |
| Revenue (TTM) | €2.62b |
Is 1BMRN overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 1BMRN income statement (TTM) | |
|---|---|
| Revenue | US$3.09b |
| Cost of Revenue | US$577.87m |
| Gross Profit | US$2.52b |
| Other Expenses | US$2.00b |
| Earnings | US$520.42m |
Last Reported Earnings
Sep 30, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | 2.71 |
| Gross Margin | 81.32% |
| Net Profit Margin | 16.82% |
| Debt/Equity Ratio | 9.9% |
How did 1BMRN perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/02/03 19:52 |
| End of Day Share Price | 2026/02/03 00:00 |
| Earnings | 2025/09/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
BioMarin Pharmaceutical Inc. is covered by 51 analysts. 15 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Jack Allen | Baird |
| Ying Huang | Barclays |
| Huidong Wang | Barclays |